NRNP 6665 Final Exam Test NEWEST
2025-2026 VERSION EXAMS With
Comprehensive Questions and Well
Elaborated Correct Answers GRADED
A+
Professional Academic Assistance Services
Services Offered
Proctored Exam Assistance
Online Class Management (Full Course Support)
Exam Preparation & Study Materials
Assignments and Coursework Support
Essays and Research Papers
Discussion Posts and Replies
,Question 18:
Christine is a 9-year-old female who presents for care after having been placed in the local foster care
system. She has been in and out of foster care for the last 4 years after her parents were killed in an
automobile accident. Christine has been placed in a variety of homes and residential care facilities. The
PMHNP recognizes that Christine is at high risk for: - correct ans:A. Dissociative disorders
B. Post-traumatic stress disorder
C. Impulse-control disorder
D. Attachment disorder
Question 7:
Caylee is a 5-year-old girl who is referred for evaluation by child protective services. She was recently
removed from her biological family and placed in foster care, as her home environment was reportedly
unsafe due to conditions of extreme neglect. Her foster mother reports that Caylee is very quiet and
withdrawn and always appears sad and disinterested in her surroundings; however, she becomes very
irritable when anything unexpected or unplanned occurs. The foster mother became very concerned
when it appeared that Caylee was hallucinating. The PMHNP considers that: - correct ans:A. Caylee is at
high risk for suicide and precautions should be taken
B. The hallucinations are consistent with brief psychotic disorder or schizophrenia
C. The history and reported symptoms are typical of depressive disorder in young children
D. This is a common situation when prepubertal children are removed from the biological parents
regardless of how dysfunctional they are
Question 2:
Debi is a 15-year-old girl who is currently being treated for depression. Her parents have been very
proactive and involved in her care, and Debi has achieved remission 2 months after beginning treatment
with a combination of pharmacotherapy and cognitive behavioral therapy. While counseling Debi's
parents about important issues in management, the PMHNP advises that: - correct ans:A. There is a >
50% likelihood that Debi's younger sibling will develop depressive symptoms
B. The mean length of major depressive episode in adolescents is 4 months
C. 20 to 40% of adolescents who have major depressive disorder will develop bipolar I within 5 years
D. Adolescent-onset depression typically need long-term pharmacologic management to prevent
relapses
Agomelatine - correct ans:Brand: Valdoxan
,-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase to 50 mg/day at bedtime
Amitriptyline (Elavil) - correct ans:Tricyclic antidepressant.
Aripiprazole (Abilify) - correct ans:Treatment for depression. Atypical antipsychotic. "Dopamine
stabilizer". Dopamine receptor antagonist in high concentration and also stimulates increase of
dopamine in low concentrations. Side effects: insomnia, akathisia.
Brexpiprazole (Rexulti) - correct ans:Treatment for depression. Atypical antipsychotic
Bupropion (Wellbutrin) - correct ans:Antidepressant and smoking cessation aid, It can treat depression
and help people quit smoking. It can also prevent depression caused by seasonal affective disorder
(SAD).
Citalopram (Celexa) - correct ans:Antidepressant, SSRI: 20-40 mg qd.
Clomipramine (Anafranil) - correct ans:-Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradrenaline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking the serotonin reuptake pump (transporter), -
Desensitization of serotonin receptors, especially serotonin 1A receptors
-Increases noradrenergic neurotransmission by blocking the norepinephrine reuptake pump
(transporter), -Desensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of the brain
, **FDA Approved for Pediatrics in tx Obsessive-compulsive disorder (OCD) (ages 10 and older)
*Off-Label for Pediatric Use: Depression, Severe and treatment-resistant, depression, Cataplexy
syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
Cyamemazine (Tercian) - correct ans:Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist, serotonin dopamine
antagonist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, including mood disorders and personality disorders
(short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
2025-2026 VERSION EXAMS With
Comprehensive Questions and Well
Elaborated Correct Answers GRADED
A+
Professional Academic Assistance Services
Services Offered
Proctored Exam Assistance
Online Class Management (Full Course Support)
Exam Preparation & Study Materials
Assignments and Coursework Support
Essays and Research Papers
Discussion Posts and Replies
,Question 18:
Christine is a 9-year-old female who presents for care after having been placed in the local foster care
system. She has been in and out of foster care for the last 4 years after her parents were killed in an
automobile accident. Christine has been placed in a variety of homes and residential care facilities. The
PMHNP recognizes that Christine is at high risk for: - correct ans:A. Dissociative disorders
B. Post-traumatic stress disorder
C. Impulse-control disorder
D. Attachment disorder
Question 7:
Caylee is a 5-year-old girl who is referred for evaluation by child protective services. She was recently
removed from her biological family and placed in foster care, as her home environment was reportedly
unsafe due to conditions of extreme neglect. Her foster mother reports that Caylee is very quiet and
withdrawn and always appears sad and disinterested in her surroundings; however, she becomes very
irritable when anything unexpected or unplanned occurs. The foster mother became very concerned
when it appeared that Caylee was hallucinating. The PMHNP considers that: - correct ans:A. Caylee is at
high risk for suicide and precautions should be taken
B. The hallucinations are consistent with brief psychotic disorder or schizophrenia
C. The history and reported symptoms are typical of depressive disorder in young children
D. This is a common situation when prepubertal children are removed from the biological parents
regardless of how dysfunctional they are
Question 2:
Debi is a 15-year-old girl who is currently being treated for depression. Her parents have been very
proactive and involved in her care, and Debi has achieved remission 2 months after beginning treatment
with a combination of pharmacotherapy and cognitive behavioral therapy. While counseling Debi's
parents about important issues in management, the PMHNP advises that: - correct ans:A. There is a >
50% likelihood that Debi's younger sibling will develop depressive symptoms
B. The mean length of major depressive episode in adolescents is 4 months
C. 20 to 40% of adolescents who have major depressive disorder will develop bipolar I within 5 years
D. Adolescent-onset depression typically need long-term pharmacologic management to prevent
relapses
Agomelatine - correct ans:Brand: Valdoxan
,-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase to 50 mg/day at bedtime
Amitriptyline (Elavil) - correct ans:Tricyclic antidepressant.
Aripiprazole (Abilify) - correct ans:Treatment for depression. Atypical antipsychotic. "Dopamine
stabilizer". Dopamine receptor antagonist in high concentration and also stimulates increase of
dopamine in low concentrations. Side effects: insomnia, akathisia.
Brexpiprazole (Rexulti) - correct ans:Treatment for depression. Atypical antipsychotic
Bupropion (Wellbutrin) - correct ans:Antidepressant and smoking cessation aid, It can treat depression
and help people quit smoking. It can also prevent depression caused by seasonal affective disorder
(SAD).
Citalopram (Celexa) - correct ans:Antidepressant, SSRI: 20-40 mg qd.
Clomipramine (Anafranil) - correct ans:-Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradrenaline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking the serotonin reuptake pump (transporter), -
Desensitization of serotonin receptors, especially serotonin 1A receptors
-Increases noradrenergic neurotransmission by blocking the norepinephrine reuptake pump
(transporter), -Desensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of the brain
, **FDA Approved for Pediatrics in tx Obsessive-compulsive disorder (OCD) (ages 10 and older)
*Off-Label for Pediatric Use: Depression, Severe and treatment-resistant, depression, Cataplexy
syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
Cyamemazine (Tercian) - correct ans:Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist, serotonin dopamine
antagonist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, including mood disorders and personality disorders
(short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
